Winstrol (Stanozolol)
FDA ApprovedDHT-Derived Anabolic Steroid | Cutting & Athletic Performance
Community Research
Join others researching Winstrol — share findings, ask questions, and learn from real experiences
Winstrol is the brand name for stanozolol, a synthetic anabolic-androgenic steroid derived from dihydrotestosterone (DHT). It was developed in 1962 by Winthrop Laboratories and approved by the FDA for the treatment of hereditary angioedema, a condition characterized by episodic swelling of the face, extremities, genitals, bowel wall, and upper airway. Stanozolol is structurally unique among DHT derivatives due to the addition of a pyrazole group fused to the A-ring, which significantly alters its pharmacological profile. It possesses a high anabolic-to-androgenic ratio (320:30 relative to methyltestosterone), making it one of the more anabolic oral steroids available. Winstrol does not aromatize to estrogen, producing no estrogenic side effects such as water retention or gynecomastia, which has made it a staple compound in cutting and pre-contest bodybuilding protocols. It is available in both oral tablet and injectable aqueous suspension forms, with both preparations being 17-alpha-alkylated and therefore hepatotoxic. Winstrol gained widespread notoriety after sprinter Ben Johnson tested positive for it following his gold medal performance at the 1988 Seoul Olympics, which remains one of the most publicized doping cases in sports history.
Stanozolol exerts its effects through binding to the intracellular androgen receptor (AR), promoting nitrogen retention, protein synthesis, and red blood cell production. As a DHT derivative, it cannot be aromatized by the aromatase enzyme, eliminating estrogen-mediated side effects. The pyrazole modification to the A-ring distinguishes stanozolol from other DHT derivatives by enhancing its oral bioavailability and altering its receptor binding characteristics. Stanozolol has a notable effect on sex hormone-binding globulin (SHBG), suppressing it more potently than most other anabolic steroids, which increases the fraction of free (bioactive) testosterone and other steroids in circulation. This SHBG-lowering property makes it particularly effective when stacked with other compounds. Stanozolol also stimulates collagen synthesis, though paradoxically it is associated with joint discomfort, likely due to its potent anti-estrogenic environment reducing synovial fluid production. It increases erythropoiesis through enhanced erythropoietin production, contributing to improved oxygen delivery. In hereditary angioedema, stanozolol increases serum levels of C1-esterase inhibitor and C4 complement, reducing the frequency and severity of angioedema attacks through a mechanism distinct from its anabolic properties.
Molecular Data
Research Indications
FDA-approved indication. Stanozolol increases plasma levels of C1-esterase inhibitor and C4 complement, reducing the frequency and severity of angioedema episodes characterized by localized swelling of the skin, mucous membranes, and internal organs.
Previously used to stimulate erythropoiesis in patients with aplastic anemia and other bone marrow failure states. Largely replaced by erythropoietin-stimulating agents and other modern therapies, though it demonstrated efficacy in stimulating red blood cell production.
Widely used during caloric deficit phases to preserve lean mass and enhance muscle hardness, vascularity, and definition. The absence of water retention produces a dry, striated appearance that is highly valued in competitive bodybuilding.
Provides significant increases in maximal and explosive strength without substantial body weight gain. Historically popular in weight-class-restricted sports, track and field, and combat sports for this reason.
Enhances speed and power output through improved neuromuscular efficiency, increased red blood cell count, and enhanced protein synthesis. The lack of water weight gain is advantageous for athletes where power-to-weight ratio is critical.
Anti-catabolic properties help preserve lean tissue during aggressive caloric restriction. The potent SHBG suppression enhances free testosterone levels, further supporting muscle preservation.
Dosing Protocols
Winstrol is available as an oral tablet, typically in 10 mg and 50 mg dosages. As a 17-alpha-alkylated steroid, it survives first-pass hepatic metabolism but carries significant hepatotoxic potential. Oral winstrol has a half-life of approximately 9 hours, necessitating split dosing for stable blood levels. The oral form is the most commonly used and is known for being particularly harsh on lipid profiles and liver values compared to most other oral steroids.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Medical - Hereditary Angioedema | 2 mg three times daily | Three times daily | Oral |
| Performance - Conservative | 25 mg/day | Split into 2-3 doses daily | Oral |
| Performance - Standard | 50 mg/day | Split into 2 doses (morning and evening) | Oral |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Severe HDL cholesterol suppression (winstrol is among the worst oral steroids for lipid damage)
- Significant LDL cholesterol elevation
- Joint dryness and pain, particularly in knees, shoulders, and elbows (notorious side effect)
- Hepatic stress with elevated liver enzymes (ALT/AST)
- Suppression of endogenous testosterone production
- Hair loss and accelerated male pattern baldness (DHT derivative, particularly harsh on hairline)
- Acne and oily skin
- Tendon and ligament stress due to rapid strength gains combined with reduced joint lubrication
- Dry, painful shin splints during cardiovascular exercise
Stop Signs - Discontinue if:
- Yellowing of skin or eyes (jaundice, indicating significant hepatic dysfunction)
- Severe or persistent abdominal pain, especially in the upper right quadrant
- Dark-colored urine or clay-colored stools (signs of liver injury)
- Sudden severe joint pain or tendon pain suggesting possible rupture
- Unusual or prolonged bleeding or bruising
- Chest pain, difficulty breathing, or signs of cardiovascular distress
- Signs of virilization in women that persist or worsen (discontinue immediately)
Contraindications
- Known or suspected prostate cancer
- Breast cancer in males
- Breast cancer with hypercalcemia in females
- Pregnancy (Category X - known to cause fetal harm)
- Severe hepatic dysfunction or active liver disease
- Nephrosis or nephrotic phase of nephritis
- Pre-existing severe cardiovascular disease or dyslipidemia
- Hypersensitivity to stanozolol or any formulation component
Quality Checklist
Good Signs
- Pharmaceutical-grade product from a verified manufacturer (Winstrol, Stromba, or authorized generic stanozolol)
- Proper labeling with correct dosage per tablet, lot number, and expiration date
- Tablets are uniform in size, color, and shape with consistent imprinting
- Injectable suspension is a milky white aqueous solution with microcrystals that resuspend evenly when shaken
- Third-party lab testing confirming identity, potency, and absence of contaminants
- Stored in original packaging, protected from moisture and light
Warning Signs
- Underground lab (UGL) product without pharmaceutical-grade verification
- Injectable solution that appears oil-based rather than water-based (may be a different compound)
- Tablets with inconsistent sizing, crumbling, or no imprint
- No third-party certificate of analysis available
- Packaging that appears unprofessional or has spelling errors
Bad Signs
- Product with no labeling or verifiable source information
- Lab testing reveals underdosed, overdosed, or substituted compound
- Injectable suspension that does not resuspend when shaken or contains visible particulate matter
- Contaminated product with heavy metals, bacteria, or undisclosed active ingredients
- Expired product or product stored improperly (excessive heat, moisture exposure)
- Severe or unexpected side effects suggesting mislabeled or adulterated product
References
- Comparative Androgenic, Myotrophic, and Antigonadotrophic Properties of Some Anabolic SteroidsPotts, G.O., Arnold, A., Beyler, A.L.Endocrinology (1976)
Established the anabolic-to-androgenic ratio of stanozolol relative to methyltestosterone, demonstrating its high anabolic potency (320) with relatively low androgenic activity (30), supporting its use in clinical settings where anabolic effects are desired with minimal virilization.
- Effect of Stanozolol on the Frequency and Severity of Attacks of Hereditary AngioedemaSheffer, A.L., Fearon, D.T., Austen, K.F.New England Journal of Medicine (1981)
Demonstrated that stanozolol significantly reduced the frequency and severity of hereditary angioedema attacks by increasing serum levels of C1-esterase inhibitor and C4 complement. Established the clinical basis for FDA approval in hereditary angioedema prophylaxis.
- The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal MenBhasin, S., Storer, T.W., Berman, N., et al.New England Journal of Medicine (1996)
Landmark study on supraphysiologic androgens and muscle growth. While focused on testosterone, this study established the dose-dependent relationship between anabolic-androgenic steroids and lean mass accretion, providing foundational evidence applicable to all anabolic agents including stanozolol.
- Hepatic Effects of 17-Alpha-Alkylated Anabolic-Androgenic SteroidsWestaby, D., Ogle, S.J., Paradinas, F.J., Randell, J.B., Murray-Lyon, I.M.Lancet (1977)
Documented hepatic complications including cholestatic jaundice and peliosis hepatis associated with 17-alpha-alkylated anabolic steroids including stanozolol. Established the clinical importance of hepatic monitoring during therapy with oral anabolic steroids.
- Oral Anabolic-Androgenic Steroids and Lipid MetabolismHartgens, F., Kuipers, H.Sports Medicine (2004)
Comprehensive review documenting the adverse lipid effects of oral anabolic steroids, with stanozolol identified as one of the most disruptive compounds for lipid metabolism. HDL reductions of 33-71% and LDL increases of 29-61% were reported with stanozolol use, exceeding the lipid impact of most other oral anabolic steroids.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.